Needham & Company

Arcutis Announces Proposed Public Offering

Retrieved on: 
Wednesday, February 28, 2024
Varick Street, Attention, Mizuho, Lexington Avenue, Prospectus, Telephone, 2nd Floor, Floor, Sale, Morgan Stanley, Madison Avenue, Guggenheim, Needham & Company, Guggenheim Partners, Security (finance)

All of the shares of common stock and pre-funded warrants in this offering are being sold by Arcutis.

Key Points: 
  • All of the shares of common stock and pre-funded warrants in this offering are being sold by Arcutis.
  • The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • In addition, Arcutis intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of shares of its common stock at the public offering price per share.
  • Morgan Stanley, TD Cowen, and Guggenheim Securities are acting as joint lead bookrunning managers for the proposed offering.

Astera Labs Announces Launch of Initial Public Offering

Retrieved on: 
Friday, March 8, 2024
Apps, Applications, Technology, Semiconductor, Other Technology, Software, Networks, Hardware, Data Management, Artificial Intelligence, Varick Street, Attention, Exchange, J.P. Morgan & Co., Prospectus, J. P. Morgan, 2nd Floor, Sale, Capital Group Companies, Morgan Stanley, Needham & Company, Roth Capital Partners, Evercore, Jefferies, Security (finance)

Astera Labs, Inc. (“Astera Labs”) today announced the launch of its initial public offering of 17,800,000 shares of its common stock.

Key Points: 
  • Astera Labs, Inc. (“Astera Labs”) today announced the launch of its initial public offering of 17,800,000 shares of its common stock.
  • The offering consists of 14,788,903 shares of common stock offered by Astera Labs and 3,011,097 shares of common stock to be sold by certain of Astera Labs’ existing stockholders.
  • In addition, the underwriters will have a 30-day option to purchase up to an additional 2,670,000 shares of common stock from Astera Labs at the initial public offering price, less underwriting discounts and commissions.
  • The initial public offering price is expected to be between $27.00 and $30.00 per share.

NAPCO Security Technologies Announces Pricing of Secondary Public Offering of Up to 2,300,000 Shares of Common Stock by Selling Stockholder

Retrieved on: 
Wednesday, March 6, 2024
NAPCO, Lexington Avenue, Prospectus, Telephone, Sale, Form, Communication, Needham & Company, Security (finance), NSSC, Offering

The shares are being sold by the Company's Chairman of the Board and President and Chief Executive Officer, Richard L. Soloway (the "Selling Stockholder").

Key Points: 
  • The shares are being sold by the Company's Chairman of the Board and President and Chief Executive Officer, Richard L. Soloway (the "Selling Stockholder").
  • Additionally, the Selling Stockholder has granted the underwriters a 30-day option to purchase from the Selling Stockholder up to an additional 300,000 shares of common stock at the public offering price.
  • The Company is not issuing or selling any shares of common stock in the Offering and therefore will not receive any of the proceeds from the sale of common stock in the Offering by the Selling Stockholder.
  • The securities described above are being offered by the Selling Stockholder pursuant to an effective registration statement on Form S-3ASR (File No.

NAPCO Security Technologies Announces Secondary Public Offering of Shares of Common Stock by Selling Stockholder

Retrieved on: 
Tuesday, March 5, 2024
NAPCO, Lexington Avenue, Prospectus, Telephone, Sale, Form, Communication, Needham & Company, Security (finance), NSSC

The Selling Stockholder expects to grant the underwriters a 30-day option to purchase additional shares of common stock at the public offering price, less underwriting discounts and commissions.

Key Points: 
  • The Selling Stockholder expects to grant the underwriters a 30-day option to purchase additional shares of common stock at the public offering price, less underwriting discounts and commissions.
  • NAPCO is not issuing or selling any shares of common stock in the offering and therefore will not receive any of the proceeds from the sale of the outstanding shares of common stock by the Selling Stockholder, and the offering will not result in dilution to existing stockholders.
  • Needham & Company and TD Cowen are acting as joint book-runners for the offering, and D.A.
  • A copy of the preliminary prospectus supplement and the accompanying prospectus relating to and describing the offering will be filed with the SEC.

Elevage Medical Technologies Continues Expansion of Investment Team and Board

Retrieved on: 
Tuesday, February 27, 2024
Frazier Healthcare Partners, Teleflex, Investment, Biological engineering, Mechanical, MIT, Invention, Growth, National academy, MBA, Senior advisor, Revelation, Biomedicine, Mechanical engineering, Patent, Bard (company), Needham & Company, Yale University, Acclarent, Medtronic, Columbia University, American Institute, Management

AUSTIN, Texas, Feb. 27, 2024 /PRNewswire/ -- Elevage Medical Technologies ("Elevage"), a portfolio company of Patient Square Capital, dedicated to supporting growth-stage medical device and medical technology companies, today announced key additions to the investment team and board. Vice-Presidents Suchira Sharma and Peter Tortora join the Elevage investment team, along with Dr. Josh Makower, a Senior Advisor to Patient Square and Elevage, who will also join the Elevage Board of Directors.

Key Points: 
  • hires –
    AUSTIN, Texas, Feb. 27, 2024 /PRNewswire/ -- Elevage Medical Technologies ("Elevage"), a portfolio company of Patient Square Capital , dedicated to supporting growth-stage medical device and medical technology companies, today announced key additions to the investment team and board.
  • Vice-Presidents Suchira Sharma and Peter Tortora join the Elevage investment team, along with Dr. Josh Makower, a Senior Advisor to Patient Square and Elevage, who will also join the Elevage Board of Directors.
  • Dr. Evan Melrose, CEO of Elevage Medical, said, "We are thrilled with these three key additions to the Elevage team.
  • Dr. Makower is also the Founder & Executive Chairman of ExploraMed, a medical device incubator that has created eleven companies since 1995.

KalVista Pharmaceuticals Announces Pricing of a $160.1 Million Public Offering of Common Stock and Pre-Funded Warrants

Retrieved on: 
Thursday, February 15, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Attention, Jefferies Group, Prospectus, Capital market, Suite, Telephone, Cantor, Sale, Montgomery Street, Form, State Street, SVB Securities, Madison Avenue, KALV, Needham & Company, Security (finance)

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) (“KalVista”) today announced the pricing of its underwritten public offering of (i) 7,016,312 shares of its common stock at a price to the public of $15.25 per share and (ii) pre-funded warrants to purchase 3,483,688 shares of common stock in lieu of KalVista common stock to certain investors.

Key Points: 
  • KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) (“KalVista”) today announced the pricing of its underwritten public offering of (i) 7,016,312 shares of its common stock at a price to the public of $15.25 per share and (ii) pre-funded warrants to purchase 3,483,688 shares of common stock in lieu of KalVista common stock to certain investors.
  • The gross proceeds to KalVista from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by KalVista, are expected to be $160.1 million.
  • In addition, KalVista has granted the underwriters a 30-day option to purchase up to an additional 1,575,000 shares of common stock at the public offering price, less underwriting discounts and commissions.
  • All of the shares of common stock and pre-funded warrants are being offered by KalVista.

Autolus Announces Pricing of Underwritten Offering

Retrieved on: 
Thursday, February 8, 2024
Security (finance), ADS, Madison Avenue, Telephone, Mizuho Securities, Attention, Prospectus, BioNTech, European Economic Area, Jefferies Group, American depositary receipt, Sale, Needham & Company

LONDON, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the pricing of an underwritten offering in the United States of 58,333,336 American Depositary Shares (“ADSs”) representing 58,333,336 ordinary shares at a public offering price of $6.00 per ADS, for total gross proceeds of $350 million.

Key Points: 
  • LONDON, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the pricing of an underwritten offering in the United States of 58,333,336 American Depositary Shares (“ADSs”) representing 58,333,336 ordinary shares at a public offering price of $6.00 per ADS, for total gross proceeds of $350 million.
  • All ADSs sold in the offering were offered by Autolus.
  • The offering is expected to close on February 12, 2024, subject to customary closing conditions.
  • Jefferies LLC and Truist Securities, Inc. are acting as joint bookrunners for the offering.

Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Retrieved on: 
Friday, February 2, 2024
Security (finance), SAN, Bank of America, Genetically modified bacteria, SVB Securities, Madison Avenue, Telephone, Guggenheim Partners, Exercise, Equity capital markets, Cantor, Attention, Prospectus, BofA Securities, Jefferies Group, Evercore, Sale, Needham & Company, State Street

This includes the exercise in full by the underwriters of their option to purchase up to 1,757,812 additional shares of common stock at the public offering price per share, less underwriting discounts and commissions.

Key Points: 
  • This includes the exercise in full by the underwriters of their option to purchase up to 1,757,812 additional shares of common stock at the public offering price per share, less underwriting discounts and commissions.
  • The aggregate gross proceeds to Vaxcyte from this offering were approximately $862.5 million, before deducting underwriting discounts and commissions and other offering expenses payable by Vaxcyte.
  • BofA Securities, Jefferies, Leerink Partners LLC, Evercore ISI, Guggenheim Securities and Cantor acted as joint book-running managers for the offering.
  • BTIG and Needham & Company acted as lead managers for the offering.

Vaxcyte Announces Pricing of $750 Million Public Offering

Retrieved on: 
Wednesday, January 31, 2024
Security (finance), SAN, Bank of America, Genetically modified bacteria, SVB Securities, Madison Avenue, Telephone, Guggenheim Partners, Exercise, Equity capital markets, Cantor, Attention, Prospectus, BofA Securities, Jefferies Group, Evercore, Sale, Needham & Company, State Street

Vaxcyte is selling 10,937,500 shares of common stock and pre-funded warrants to purchase 781,250 shares of common stock in the offering.

Key Points: 
  • Vaxcyte is selling 10,937,500 shares of common stock and pre-funded warrants to purchase 781,250 shares of common stock in the offering.
  • The shares of common stock are being sold at a public offering price of $64.00 per share, and the pre-funded warrants are being sold at a public offering price of $63.999 per pre-funded warrant.
  • The aggregate gross proceeds to Vaxcyte from this offering are expected to be approximately $750.0 million, before deducting underwriting discounts and commissions and other offering expenses, and excluding the exercise of any pre-funded warrants.
  • All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Vaxcyte.

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

Retrieved on: 
Tuesday, January 30, 2024
Security (finance), SAN, Bank of America, Genetically modified bacteria, SVB Securities, Madison Avenue, Telephone, Guggenheim Partners, Equity capital markets, Cantor, Attention, Prospectus, BofA Securities, Jefferies Group, Evercore, Sale, Needham & Company, State Street

All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Vaxcyte.

Key Points: 
  • All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Vaxcyte.
  • Vaxcyte intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of its common stock offered in the public offering (including shares underlying the pre-funded warrants).
  • The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • BofA Securities, Jefferies, Leerink Partners, Evercore ISI, Guggenheim Securities and Cantor are acting as joint book-running managers for the offering.